Venclexta is indicated for daily use after detection of 17p deletion is confirmed through the use of the FDA-approved companion diagnostic Vysis CLL FISH probe kit. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.
Chronic Lymphocytic Leukemia is one of the most common types of leukemia in adults, with approximately 15,000 new cases diagnosed each year. CLL is characterized by the progressive accumulation of abnormal lymphocytes, a type of white blood cell. Patients with CLL who have a 17p deletion lack a portion of the chromosome that acts to suppress cancer growth. This chromosomal abnormality occurs in approximately 10 percent of patients with untreated CLL and in approximately 20 percent of patients with relapsed CLL.
Venclexta/venetoclax Side effectsThe most common side effects of Venclexta include
- Low white blood cell count
- Upper respiratory tract infection
- Low platelet count (thrombocytopenia)
Serious complications can include
- Neutropenia with fever
- Autoimmune hemolytic anemia
- Metabolic abnormalities known as tumor lysis syndrome.
- Live attenuated vaccines should not be given to patients taking Venclexta.